CIK 0001390478 · Non-accelerated filer<br>Smaller reporting company
SELLAS Life Sciences Group, Inc.
Sign in to watch- Ticker
- SLS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 6462005278
- Business address
- 7 TIMES SQUARE, SUITE 2503, NEW YORK, NY, 10036
- Former names
- GALENA BIOPHARMA, INC., Galena Biopharma, Inc., RXI PHARMACEUTICALS CORP
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-02-02 | WOOD BARBARA A EVP, Gen. Counsel, Corp. Sec. | Grant or award · Stock Option (Right to Buy) | +80,000 | 80,000 | ||
| 2023-02-02 | Burns John Thomas CFO | Grant or award | +20,000 | 49,347 | ||
| 2023-02-02 | Burns John Thomas CFO | Grant or award · Stock Option Right to Buy) | +75,000 | 75,000 | ||
| 2023-02-02 | Stergiou Angelos M. President and CEO | Grant or award | +58,000 | 219,689 | ||
| 2023-02-02 | Stergiou Angelos M. President and CEO | Grant or award · Stock Option (Right to Buy) | +217,500 | 217,500 | ||
| 2023-02-02 | Francomano Robert Chief Commercial Officer | Grant or award | +12,000 | 12,000 | ||
| 2023-02-02 | Francomano Robert Chief Commercial Officer | Grant or award · Stock Option (Right to Buy) | +45,000 | 45,000 | ||
| 2023-02-02 | Varian John Director | Grant or award | +2,500 | 4,400 | ||
| 2023-02-02 | Varian John Director | Grant or award · Stock Option (Right to Buy) | +9,500 | 9,500 | ||
| 2023-02-02 | Wasman Jane Director | Grant or award | +2,500 | 4,400 | ||
| 2023-02-02 | Wasman Jane Director | Grant or award · Stock Option (Right to Buy) | +9,500 | 9,500 | ||
| 2023-02-02 | VAN NOSTRAND ROBERT L Director | Grant or award | +2,500 | 4,400 | ||
| 2023-02-02 | VAN NOSTRAND ROBERT L Director | Grant or award · Stock Option (Right to Buy) | +9,500 | 9,500 | ||
| 2023-02-02 | SCHEINBERG DAVID A Director | Grant or award | +2,500 | 4,582 | ||
| 2023-02-02 | SCHEINBERG DAVID A Director | Grant or award · Stock Option (Right to Buy) | +9,500 | 9,500 | ||
| 2023-02-02 | Kalin Katherine Bach Director | Grant or award | +2,500 | 2,500 | ||
| 2023-02-02 | Kalin Katherine Bach Director | Grant or award · Stock Option (Right to Buy) | +9,500 | 9,500 | ||
| 2022-12-05 | Stergiou Angelos M. President and CEO | Sale | −6,494 | $2.61 | $17K | 161,689 |
| 2022-12-05 | Burns John Thomas Senior VP, Finance & CAO | Sale | −1,159 | $2.59 | $3K | 29,347 |
| 2022-12-05 | WOOD BARBARA A EVP, Gen. Counsel, Corp. Sec. | Sale | −2,153 | $2.59 | $6K | 56,344 |
Page 4 of 8 · 141 trades